This page is part of the FHIR Specification (v1.0.0: DSTU 2 Ballot 3). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions

1.25.4.1.1070 v3 Code System substanceAdminSubstitution

This code system (http://hl7.org/fhir/v3/substanceAdminSubstitution) is defined as part of HL7 v3.

Summary

Defining URL:

http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution

Name:

v3 Code System substanceAdminSubstitution

Definition:

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

OID:

(for OID based terminology systems)

System URL:

http://hl7.org/fhir/v3/substanceAdminSubstitution

System OID:

2.16.840.1.113883.5.1070

Source Resource

XML / JSON

This value set is not currently used

1.25.4.1.1070.1 Content Logical Definition

This value set has an inline code system http://hl7.org/fhir/v3/substanceAdminSubstitution, which defines the following codes:

Lvl	Code	Display	Definition
1	_ActSubstanceAdminSubstitutionCode	ActSubstanceAdminSubstitutionCode	Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.
2	E	equivalent	Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
3	EC	equivalent composition	Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
4	BC	brand composition	Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven
4	G	generic composition	Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
3	TE	therapeutic alternative	Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet
4	TB	therapeutic brand	Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet
4	TG	therapeutic generic	Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine
2	F	formulary	Description: This substitution was performed or is permitted based on formulary guidelines.
2	N	none	No substitution occurred or is permitted.